Research Program Unit in Systems Oncology, Oncosys, Medical Faculty, University of Helsinki, Helsinki, Finland; Coagulation Disorders Unit, Department of Hematology, Helsinki University Hospital, Helsinki, Finland.
Department of Cell and Developmental Biology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Thromb Haemost. 2023 Nov;21(11):3024-3032. doi: 10.1016/j.jtha.2023.05.009. Epub 2023 May 18.
The multiple roles of red blood cells (RBCs) are often neglected as contributors in hemostasis and thrombosis. Proactive opportunities to increase RBC numbers, either acutely or subacutely in the case of iron deficiency, are critical as RBCs are the cellular elements that initiate hemostasis together with platelets and stabilize fibrin and clot structure. RBCs also possess several functional properties to assist hemostasis: releasing platelet agonists, promoting shear force-induced von Willebrand factor unfolding, procoagulant capacity, and binding to fibrin. Additionally, blood clot contraction is important to compress RBCs to form a tightly packed array of polyhedrocytes, making an impermeable seal for hemostasis. All these functions are important for patients having intrinsically poor capacity to cease bleeds (ie, hemostatic disorders) but, conversely, can also play a role in thrombosis if these RBC-mediated reactions overshoot. One acquired example of bleeding with anemia is in patients treated with anticoagulants and/or antithrombotic medication because upon initiation of these drugs, baseline anemia doubles the risk of bleeding complications and mortality. Also, anemia is a risk factor for reoccurring gastrointestinal and urogenital bleeds, pregnancy, and delivery complications. This review summarizes the clinically relevant properties and profiles of RBCs at various steps of platelet adhesion, aggregation, thrombin generation, and fibrin formation, including both structural and functional elements. Regarding patient blood management guidelines, they support minimizing transfusions, but this approach does not deal with severe inherited and acquired bleeding disorders where a poor hemostatic propensity is exacerbated by limited RBC availability, for which future guidance will be needed.
红细胞(RBC)在止血和血栓形成中的多重作用常常被忽视。无论是在缺铁的急性情况下还是亚急性情况下,积极增加 RBC 数量的机会都至关重要,因为 RBC 是与血小板一起启动止血并稳定纤维蛋白和血凝块结构的细胞成分。RBC 还具有几种辅助止血的功能特性:释放血小板激动剂、促进剪切力诱导的血管性血友病因子展开、促凝能力以及与纤维蛋白结合。此外,血块收缩对于将 RBC 压缩成紧密排列的多面体细胞阵列以形成止血的不透水密封也很重要。所有这些功能对于那些内在止血能力差的患者(即止血障碍)都很重要,但相反,如果这些 RBC 介导的反应过度,也可能在血栓形成中发挥作用。一种与贫血相关的出血的获得性例子是在接受抗凝剂和/或抗血栓药物治疗的患者中,因为在开始使用这些药物后,基线贫血使出血并发症和死亡率的风险增加一倍。此外,贫血是胃肠道和泌尿生殖系统出血、妊娠和分娩并发症再发的危险因素。这篇综述总结了 RBC 在血小板黏附、聚集、凝血酶生成和纤维蛋白形成的各个步骤中的临床相关特性和特征,包括结构和功能元素。关于患者血液管理指南,它们支持尽量减少输血,但这种方法不能解决严重的遗传性和获得性出血性疾病,这些疾病的止血倾向较差,并且由于 RBC 可用性有限而加剧,因此需要未来的指导。